Black Race Remains Associated with Lower Eligibility for Screening Using 2021 US Preventive Services Task Force Recommendations Among Lung Cancer Patients at an Urban Safety Net Hospital
Authors:
- 28 November 2022
- journal article
- research article
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- Vol. 10 (6) , 2836-2843
Abstract
Objective To evaluate whether the revised US Preventive Services Task Force (USPSTF) criteria reduced inequities in lung cancer screening (LCS) eligibility among a racially diverse sample of patients with lung cancer. Methods This is a retrospective analysis of adults diagnosed with primary lung malignancies at an urban safety net hospital. For all patients and exclusively ever-smokers, χ2 tests were used to evaluate differences in LCS eligibility among socio-demographic variables using the 2013 and 2021 USPSTF criteria. Patients who were ineligible for LCS were categorized by reason for exclusion. Results Among 678 lung cancer patients (46% female, mean age 66 ± 10 years), 51% were White, and 39% were Black. Using the 2013 guidelines, White patients (57%) would have been more likely to be eligible than Black (37%) and other-race patients (35%) (P < 0.0001) at time of cancer diagnosis. Under the 2021 guidelines, White patients (68%) remained more likely to be eligible for LCS than Black (54%) and other-race patients (48%) (P = 0.0002). Among exclusively ever-smoking patients, we did not observe a significant difference in eligibility by race under the 2021 USPSTF guidelines (White [73%], Black [65%], and other-race [65%]; [P = 0.48]). Sex, ethnicity, education level, and insurance type were not associated with differential screening eligibility under either the 2013 or 2021 guidelines. Conclusion The revised 2021 USPSTF LCS guidelines may not be sufficient to eliminate racial inequities in LCS eligibility among patients who go on to be diagnosed with primary lung cancer. Differential rates of lung cancer among never-smokers may contribute to this inequity.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (T35HL1394440)
- Pfizer (65017585)
This publication has 25 references indexed in Scilit:
- Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult SmokersJAMA Oncology, 2019
- Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992–2013Cancer Epidemiology, Biomarkers & Prevention, 2017
- Comparison of Smoking History Patterns Among African American and White Cohorts in the United States Born 1890 to 1990Nicotine & Tobacco Research, 2016
- Understanding Tobacco Use Onset Among African AmericansNicotine & Tobacco Research, 2016
- Age at Cancer Diagnosis for Blacks Compared With Whites in the United StatesJNCI: Journal of the National Cancer Institute, 2015
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Baseline Characteristics of Participants in the Randomized National Lung Screening TrialJNCI: Journal of the National Cancer Institute, 2010
- Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry StudiesPLOS Medicine, 2008
- Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 casesAnnals of Oncology, 2002
- Female-male differences in patients with primary lung cancerCancer, 1987